The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 4, 1998, Pages 273-279

  Schulte, Theodor W ^a,b   Neckers, Leonard M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Vascular Medicine Branch   (United States)

Author keywords

17 Allylamino 17 demethoxygeldanamycin; HSP90; Mutant p53; p185(erbB2); Raf 1

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANSAMYCIN DERIVATIVE; ANTINEOPLASTIC AGENT; CHAPERONE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL LINE; CELL STRAIN 3T3; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

3T3 CELLS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BENZOQUINONES; CELL DIVISION; ENZYME INHIBITORS; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MICE; MUTATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-RAF; QUINONES; RECEPTOR, ERBB-2; RIFABUTIN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031875042     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050817     Document Type: Article

References (37)

1. An WG, Schnur RC, Neckers L, Blagosklonny MV (1997) Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates well with antiproliferative activity. Cancer Chemother Pharmacol 40: 60
2. Bartek J, Iggo R, Gannon J, Lane DP (1990) Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 5: 893
3. Blagosklonny MV, Toretsky J, Neckers L (1995) Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene 11: 933
4. Blagosklonny MV, Toretsky J, Bohen S, Neckers L (1996) Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc Natl Acad Sci USA 93: 8379
5. Brugge JS (1986) Interaction of the Rous sarcoma virus protein pp60src with the cellular proteins pp50 and pp90. Curr Top Microbiol Immunol 123: 1
6. Brugge J, Yonemoto W, Darrow D (1983) Interaction between the Rous sarcoma virus transforming protein and two cellular phosphoproteins: analysis of the turnover and distribution of this complex. Mol Cell Biol 3: 9
7. Chavany C, Mimnaugh E, Miller P, Bitton R, Nguyen P, Trepel J, Whitesell L, Schnur R, Moyer J, Neckers L (1996) p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2 GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. J Biol Chem 271: 4974
8. DeBoer C, Meulman PA, Wnuk RJ, Peterson DH (1970) Geldanamycin, a new antibiotic. J Antibiot (Tokyo) 23: 442
9. 1 mice and Fisher 344 rats. Proc Am Assoc Cancer Res 38: 308
10. Johnson JL, Toft DO (1995) Binding of p23 and hsp90 during assembly with the progesterone receptor. Mol Endocrinol 9: 670
11. Kovach JS, McGovern RM, Cassady JD, Swanson SK, Wold LE, Vogelstein B, Sommer SS (1991) Direct sequencing from touch preparations of human carcinomas: analysis of p53 mutations in breast carcinomas (see comments). J Natl Cancer Inst 83: 1004
12. Levine AJ, Momand J, Finlay CA (1991) The p53 tumour suppressor gene. Nature 351: 453
13. Magnuson NS, Beck T, Vahidi H, Hahn H, Smola U, Rapp UR (1994) The Raf-1 serine/threonine protein kinase. Semin Cancer Biol 5: 247
14. Miller P, DiOrio C, Moyer M, Schnur RC, Bruskin A, Cullen W, Moyer JD (1994) Depletion of the erbB-2 gene product pi85 by benzoquinoid ansamycins. Cancer Res 54: 2724
15. Miller P, Schnur RC, Barbacci E, Moyer MP, Moyer JD (1994) Binding of benzoquinoid ansamycins to p100 correlates with their ability to deplete the erbB2 gene product p185. Biochem Biophys Res Commun 201: 1313
16. Morrison DK, Cutler RE (1997) The complexity of Raf-1 regulation. Curr Opin Cell Biol 9: 174
17. Murakami Y, Fukazawa H, Mizuno S, Uehara Y (1994) Conversion of epidermal growth factor (FGF) into a stimulatory ligand for A431-cell growth by herbimycin A by decreasing the level of expression of EGF receptor. Biochem J 301 (Pt1): 57
18. Murakami Y, Mizuno S, Uehara Y (1994) Accelerated degradation of 160 kDa epidermal growth factor (EGF) receptor precursor by the tyrosine kinase inhibitor herbimycin A in the endoplasmic reticulum of A431 human epidermoid carcinoma cells. Biochem J 301 (Pt1): 63
19. Okahe M, Uehara Y, Miyagishima T, Itaya T, Tanaka M, Kuni EY, Kurosawa M, Miyazaki T (1992) Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210ber/abl and preferential inhibition on Ph1-positive leukemia cell growth. Blood 80: 1330
20. Omura S, Iwai Y, Takahashi Y, Sadakane N, Nakagawa A, Oiwa H, Hasegawa Y, Ikai T (1979) Herbimycin, a new antibiotic produced by a strain of Streptomyces. J Antibiot (Tokyo) 32: 255
21. Page J, Heath J, Fulton R, Yalkowsky E, Tabibi E, Tomaszewski J, Smith A, Rodman L (1997) Comparison of geldanamycin (NSC-122750) and 17-allylaminogeldanamycin (NSC-330507D) toxicity in rats. Proc Am Assoc Cancer Res 38: 308
22. Schnur RC, Corman ML, Gallaschun RJ, Cooper BA, Dee MF, Doty JL, Muzzi ML, Moyer JD, DiOrio CI, Barbacci EG, et al (1995) Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J Med Chem 38: 3806
23. Schulte TW, Blagosklonny MV, Ingui C, Neckers L (1995) Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem 270: 24585
24. Schulte TW, Blagosklonny MV, Romanova L, Mushinski JF, Monia BP, Johnston JF, Nguyen P, Trepel J, Neckers LM (1996) Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway. Mol Cell Biol 16: 5839
25. Smith DF, Whitesell L, Nair SC, Chen S, Prapapanich V, Rimerman RA (1995) Progesterone receptor structure and function altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol 15: 6804
26. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP (1997) Crystal structure of an HSP90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89: 239
27. Stepanova L, Leng X, Parker SB, Harper JW (1996) Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev 10: 1491
28. Sullivan W, Stensgard B, Caucutt G, Bartha B, McMahon N, Alnemri ES, Litwack G, Toft D (1997) Nucleotides and two Cunclional states of hsp90. J Biol Chem 272: 8007
29. Supko JG, Hickman RL, Grever MR, Malspeis L (1995) Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36: 305
30. Uehara Y, Fukazawa H (1991) Use and selectivity of herbimycin A as inhibitor of protein-tyrosine kinases. Methods Enzymol 201: 370
31. Ueharu Y, Hori M, Takeuchi T, Umezawa H (1985) Screening of agents which convert 'transformed morphology' of Rous sarcoma virus-infected rat kidney cells to 'normal morphology': identification of an active agent as herbimycin and its inhibition of intracellular src kinase. Jpn J Cancer Res 76: 672
32. Uehara Y, Hori M, Tukeuehi T, Umezawa H (1986) Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus. Mol Cell Biol 6: 2198
33. Uehura Y, Murakami Y, Mizuno S, Kawai S (1988) Inhibition of transforming activity of tyrosine kinase oncogenes by herbimycin A. Virology 164: 294
34. Uehara Y, Murakami Y, Suzukake TK, Moriya Y, Sano H, Shibata K, Omura S (1988) Effects of herbimycin derivatives on src oncogene function in relation to antitumor activity. J Antibiot (Tokyo) 41: 831
35. Whitesell L, Cook P (1996) Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells. Mol Endocrinol 10: 705
36. Whitesell L, Mimnaugh EG, De CB, Myers CE, Neckers LM (1994) Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 91: 8324
37. Whitesell L, Suthphin P, An WG, Schulte TW, Blagosklonny MV, Neckers LM (1997) Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo. Oncogene 14: 2809